SORBET

Closed

ANZ 1001: SORBET

BCT Study Chair:

Kelly-Anne Phillips

About 15% of breast cancers diagnosed are a type which is called “triple-negative”. These cancers are more resistant to treatment because they lack the three most common treatment targets known as receptors. Women diagnosed with triple-negative breast cancer usually have a poorer prognosis as their disease is more likely to spread to other sites in the body. At least 20% of triple-negative breast cancers are ER-positive. It is hoped that SORBET will show that daily treatment with tamoxifen, a low cost and well tolerated drug, can control the growth and spread of triple-negative, ER-positive metastatic breast cancer.

0

INTERNATIONAL

Total number of trial

participants internationally

5

AUSTRALIA & NEW ZEALAND

Total number of trial participants

in Australia and New Zealand

15

INSTITUTIONS

Total number of participating institutions

in Australia and New Zealand

SORBET TRANSLATIONAL RESEARCH SAMPLES

A Single Arm Phase II Study of the Efficacy of Tamoxifen in Triple Negative (oestrogen receptor alpha negative, progesterone receptor negative, HER-2 negative) but Oestrogen Receptor Beta Positive Metastatic Breast Cancer (ACTRN12610000506099)

SORBET PUBLICATIONS

2012

ANZ1001 SORBET: Study of oestrogen receptor beta and efficacy of tamoxifen, a single arm, phase II study of the efficacy of tamoxifen in triple negative but estrogen receptor beta positive metastatic breast cancer.

Phillips KA, Kiely BE, Francis PA, Boyle FM, Fox SB, Murphy L, Gebski V, Lindsay DF, Sutherland RL, Badger HD, Forbes JF. J. Clin Oncol. 2012; 30(Supp):TPS1136, Abstract

2011

ANZ 1001: SORBET, Study of Oestrogen Receptor Beta and Efficacy of Tamoxifen.

Kiely B, Phillips KA, Francis P, Boyle F, Forbes JF, Fox S, Murphy L, Gebski V, Lindsay DF, Sutherland R, Badger HD. ASCO 2011 2011; TPS126, Poster

2010

Clinical Trials Open for Participant Entry.

Forbes JF, Boyle F, Wilcken N, Lindsay DF, Leong E. COSA 2010; Poster 242, Poster

SORBET